Business strategy in drug development


Ontology type: npg:Subject  | skos:Concept     

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "id": "http://scigraph.springernature.com/ontologies/subjects/business-strategy-in-drug-development", 
    "rdfs:label": "Business strategy in drug development", 
    "sdDataset": "onto_subjects", 
    "skos:broader": [
      {
        "id": "http://scigraph.springernature.com/ontologies/subjects/drug-discovery"
      }
    ], 
    "skos:inScheme": [
      {
        "id": "http://scigraph.springernature.com/ontologies/subjects/"
      }
    ], 
    "skos:narrower": [
      {
        "id": "http://scigraph.springernature.com/ontologies/subjects/mergers-and-acquisitions"
      }, 
      {
        "id": "http://scigraph.springernature.com/ontologies/subjects/pharmacoeconomics"
      }, 
      {
        "id": "http://scigraph.springernature.com/ontologies/subjects/licensing"
      }, 
      {
        "id": "http://scigraph.springernature.com/ontologies/subjects/market-analysis"
      }, 
      {
        "id": "http://scigraph.springernature.com/ontologies/subjects/portfolio-management"
      }, 
      {
        "id": "http://scigraph.springernature.com/ontologies/subjects/public-private-partnerships"
      }, 
      {
        "id": "http://scigraph.springernature.com/ontologies/subjects/reimbursement"
      }, 
      {
        "id": "http://scigraph.springernature.com/ontologies/subjects/intellectual-property"
      }
    ], 
    "skos:prefLabel": [
      {
        "@language": "en", 
        "@value": "Business strategy in drug development"
      }
    ], 
    "type": [
      "http://www.w3.org/2004/02/skos/core#Concept", 
      "http://ns.nature.com/terms/Subject"
    ]
  }, 
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "id": "http://scigraph.springernature.com/ontologies/subjects/mergers-and-acquisitions", 
    "rdfs:label": "Mergers and acquisitions", 
    "sdDataset": "onto_subjects", 
    "skos:broader": [
      {
        "id": "http://scigraph.springernature.com/ontologies/subjects/business-strategy-in-drug-development"
      }
    ], 
    "skos:definition": [
      {
        "@language": "en", 
        "@value": "Mergers and acquisitions (M&A) involve the buying, selling, dividing and combining of different companies to achieve company goals. For example, in the pharmaceutical industry, large companies may acquire small companies with a view to enhancing the overall pipeline of potential medicines they are developing or to gain access to a proprietary technology. "
      }
    ], 
    "skos:inScheme": [
      {
        "id": "http://scigraph.springernature.com/ontologies/subjects/"
      }
    ], 
    "skos:prefLabel": [
      {
        "@language": "en", 
        "@value": "Mergers and acquisitions"
      }
    ], 
    "type": [
      "http://www.w3.org/2004/02/skos/core#Concept", 
      "http://ns.nature.com/terms/Subject"
    ]
  }, 
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "id": "http://scigraph.springernature.com/ontologies/subjects/pharmacoeconomics", 
    "rdfs:label": "Pharmacoeconomics", 
    "sdDataset": "onto_subjects", 
    "skos:altLabel": [
      {
        "@language": "en", 
        "@value": "Pharmaceutical Economics"
      }
    ], 
    "skos:broader": [
      {
        "id": "http://scigraph.springernature.com/ontologies/subjects/business-strategy-in-drug-development"
      }
    ], 
    "skos:definition": [
      {
        "@language": "en", 
        "@value": "Pharmacoeconomics is the scientific discipline concerned with the cost and value of drugs, often with the goal of optimizing the allocation of healthcare resources. For example, pharmacoeconomic studies may compare the costs of various drugs with the outcomes, such as benefits to patients receiving the drugs and costs saved by healthcare systems owing to effective treatment or prevention of a disease."
      }
    ], 
    "skos:inScheme": [
      {
        "id": "http://scigraph.springernature.com/ontologies/subjects/"
      }
    ], 
    "skos:prefLabel": [
      {
        "@language": "en", 
        "@value": "Pharmacoeconomics"
      }
    ], 
    "type": [
      "http://ns.nature.com/terms/Subject", 
      "http://www.w3.org/2004/02/skos/core#Concept"
    ]
  }, 
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "id": "http://scigraph.springernature.com/ontologies/subjects/licensing", 
    "rdfs:label": "Licensing", 
    "sdDataset": "onto_subjects", 
    "skos:altLabel": [
      {
        "@language": "en", 
        "@value": "Licensure"
      }, 
      {
        "@language": "en", 
        "@value": "Institutional Personnel Licensures"
      }, 
      {
        "@language": "en", 
        "@value": "Permits"
      }, 
      {
        "@language": "en", 
        "@value": "Institutional Personnel Licensure"
      }, 
      {
        "@language": "en", 
        "@value": "License"
      }, 
      {
        "@language": "en", 
        "@value": "Licenses"
      }, 
      {
        "@language": "en", 
        "@value": "Licensures"
      }, 
      {
        "@language": "en", 
        "@value": "Permit"
      }
    ], 
    "skos:broader": [
      {
        "id": "http://scigraph.springernature.com/ontologies/subjects/business-strategy-in-drug-development"
      }
    ], 
    "skos:definition": [
      {
        "@language": "en", 
        "@value": "Licensing is widely used in the commercialization of intellectual property such as patents on drugs or technologies. The owner of the intellectual property grants the licensee the rights to use the intellectual property, typically in return for a payment, such as a fee or royalty. "
      }
    ], 
    "skos:inScheme": [
      {
        "id": "http://scigraph.springernature.com/ontologies/subjects/"
      }
    ], 
    "skos:prefLabel": [
      {
        "@language": "en", 
        "@value": "Licensing"
      }
    ], 
    "type": [
      "http://ns.nature.com/terms/Subject", 
      "http://www.w3.org/2004/02/skos/core#Concept"
    ]
  }, 
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "id": "http://scigraph.springernature.com/ontologies/subjects/market-analysis", 
    "rdfs:label": "Market analysis", 
    "sdDataset": "onto_subjects", 
    "skos:broader": [
      {
        "id": "http://scigraph.springernature.com/ontologies/subjects/business-strategy-in-drug-development"
      }
    ], 
    "skos:definition": [
      {
        "@language": "en", 
        "@value": "Market analysis seeks to understand the dynamics of markets, with the goal of informing business strategies. For example, analysis of the current and potential future markets for drugs to treat particular diseases is used by pharmaceutical companies in decisions about where to invest in drug research and development. "
      }
    ], 
    "skos:inScheme": [
      {
        "id": "http://scigraph.springernature.com/ontologies/subjects/"
      }
    ], 
    "skos:prefLabel": [
      {
        "@language": "en", 
        "@value": "Market analysis"
      }
    ], 
    "type": [
      "http://ns.nature.com/terms/Subject", 
      "http://www.w3.org/2004/02/skos/core#Concept"
    ]
  }, 
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "id": "http://scigraph.springernature.com/ontologies/subjects/portfolio-management", 
    "rdfs:label": "Portfolio management", 
    "sdDataset": "onto_subjects", 
    "skos:broader": [
      {
        "id": "http://scigraph.springernature.com/ontologies/subjects/business-strategy-in-drug-development"
      }
    ], 
    "skos:definition": [
      {
        "@language": "en", 
        "@value": "Larger drug companies attempt to ensure consistent financial performance by managing a portfolio of products at different stages of development, from preclinical studies through to marketed products. Generally, only marketed products are bringing in revenue, and they will eventually lose patent protection and revenue from them will drop substantially, and so there is a need to develop new marketed products to maintain overall revenue, but these have a risk of failure in development to account for."
      }
    ], 
    "skos:inScheme": [
      {
        "id": "http://scigraph.springernature.com/ontologies/subjects/"
      }
    ], 
    "skos:prefLabel": [
      {
        "@language": "en", 
        "@value": "Portfolio management"
      }
    ], 
    "type": [
      "http://www.w3.org/2004/02/skos/core#Concept", 
      "http://ns.nature.com/terms/Subject"
    ]
  }, 
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "id": "http://scigraph.springernature.com/ontologies/subjects/public-private-partnerships", 
    "rdfs:label": "Public\u2013private partnerships", 
    "sdDataset": "onto_subjects", 
    "skos:altLabel": [
      {
        "@language": "en", 
        "@value": "Public Private Sector Cooperation"
      }, 
      {
        "@language": "en", 
        "@value": "Public Private Sector Partnerships"
      }, 
      {
        "@language": "en", 
        "@value": "Public-Private Sector Cooperations"
      }, 
      {
        "@language": "en", 
        "@value": "Public-Private Partnership"
      }, 
      {
        "@language": "en", 
        "@value": "Public Private Partnerships"
      }, 
      {
        "@language": "en", 
        "@value": "Public-Private Sector Cooperation"
      }, 
      {
        "@language": "en", 
        "@value": "Public-Private Sector Partnership"
      }, 
      {
        "@language": "en", 
        "@value": "Public-Private Cooperations"
      }, 
      {
        "@language": "en", 
        "@value": "Public Private Cooperation"
      }, 
      {
        "@language": "en", 
        "@value": "Public-Private Sector Partnerships"
      }, 
      {
        "@language": "en", 
        "@value": "Public-Private Cooperation"
      }, 
      {
        "@language": "en", 
        "@value": "Public-Private Partnerships"
      }
    ], 
    "skos:broader": [
      {
        "id": "http://scigraph.springernature.com/ontologies/subjects/business-strategy-in-drug-development"
      }
    ], 
    "skos:definition": [
      {
        "@language": "en", 
        "@value": "Public\u2013private partnerships are collaborations between publicly funded organizations such as academic institutions and for-profit organizations such as pharmaceutical companies. They are often set up to benefit from complementary assets of each party, such as expertise in disease biology in academic institutions and expertise and financial resources for clinical development in companies. "
      }
    ], 
    "skos:inScheme": [
      {
        "id": "http://scigraph.springernature.com/ontologies/subjects/"
      }
    ], 
    "skos:prefLabel": [
      {
        "@language": "en", 
        "@value": "Public\u2013private partnerships"
      }
    ], 
    "type": [
      "http://www.w3.org/2004/02/skos/core#Concept", 
      "http://ns.nature.com/terms/Subject"
    ]
  }, 
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "id": "http://scigraph.springernature.com/ontologies/subjects/reimbursement", 
    "rdfs:label": "Reimbursement", 
    "sdDataset": "onto_subjects", 
    "skos:altLabel": [
      {
        "@language": "en", 
        "@value": "Incentive Reimbursements"
      }, 
      {
        "@language": "en", 
        "@value": "Incentive Reimbursement"
      }, 
      {
        "@language": "en", 
        "@value": "Pay for Performance"
      }
    ], 
    "skos:broader": [
      {
        "id": "http://scigraph.springernature.com/ontologies/subjects/business-strategy-in-drug-development"
      }
    ], 
    "skos:definition": [
      {
        "@language": "en", 
        "@value": "Reimbursement is a key component of market access for a new therapeutic intervention; once it has been approved for marketing in a region or country, and its initial price determined, the manufacturer typically submits an application to an organization (such as an insurance company or a government bodies in countries that provide government-funded healthcare) that decides whether it will reimburse the company for its use by doctors to treat patients. "
      }
    ], 
    "skos:inScheme": [
      {
        "id": "http://scigraph.springernature.com/ontologies/subjects/"
      }
    ], 
    "skos:prefLabel": [
      {
        "@language": "en", 
        "@value": "Reimbursement"
      }
    ], 
    "type": [
      "http://ns.nature.com/terms/Subject", 
      "http://www.w3.org/2004/02/skos/core#Concept"
    ]
  }, 
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "id": "http://scigraph.springernature.com/ontologies/subjects/intellectual-property", 
    "rdfs:label": "Intellectual property", 
    "sdDataset": "onto_subjects", 
    "skos:altLabel": [
      {
        "@language": "en", 
        "@value": "Intellectual Properties"
      }
    ], 
    "skos:broader": [
      {
        "id": "http://scigraph.springernature.com/ontologies/subjects/business-strategy-in-drug-development"
      }
    ], 
    "skos:definition": [
      {
        "@language": "en", 
        "@value": "Intellectual property (IP), such as patents, provides legal rights to the exclusive use of the output of creative efforts. For example, a patent on a drug could provide its owner with the right to exclusively market that drug for a defined period of time in exchange for detailed public disclosure of the drug\u2019s characteristics, such as chemical structure."
      }
    ], 
    "skos:inScheme": [
      {
        "id": "http://scigraph.springernature.com/ontologies/subjects/"
      }
    ], 
    "skos:prefLabel": [
      {
        "@language": "en", 
        "@value": "Intellectual property"
      }
    ], 
    "type": [
      "http://www.w3.org/2004/02/skos/core#Concept", 
      "http://ns.nature.com/terms/Subject"
    ]
  }, 
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "id": "http://www.w3.org/2004/02/skos/core#Concept", 
    "rdfs:subClassOf": [
      {
        "id": "http://www.w3.org/2004/02/skos/core#Concept"
      }, 
      {
        "id": "http://www.w3.org/2000/01/rdf-schema#Resource"
      }
    ], 
    "sdDataset": "for_codes", 
    "type": [
      "http://www.w3.org/2000/01/rdf-schema#Resource", 
      "http://www.w3.org/2000/01/rdf-schema#Class"
    ]
  }, 
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "id": "http://scigraph.springernature.com/ontologies/subjects/drug-discovery", 
    "rdfs:label": "Drug discovery", 
    "sdDataset": "onto_subjects", 
    "skos:altLabel": [
      {
        "@language": "en", 
        "@value": "Drug Prospecting"
      }
    ], 
    "skos:broader": [
      {
        "id": "http://scigraph.springernature.com/ontologies/subjects/biological-sciences"
      }
    ], 
    "skos:definition": [
      {
        "@language": "en", 
        "@value": "Drug discovery is the process through which potential new medicines are identified. It involves a wide range of scientific disciplines, including biology, chemistry and pharmacology.   "
      }
    ], 
    "skos:inScheme": [
      {
        "id": "http://scigraph.springernature.com/ontologies/subjects/"
      }
    ], 
    "skos:narrower": [
      {
        "id": "http://scigraph.springernature.com/ontologies/subjects/business-strategy-in-drug-development"
      }, 
      {
        "id": "http://scigraph.springernature.com/ontologies/subjects/drug-screening"
      }, 
      {
        "id": "http://scigraph.springernature.com/ontologies/subjects/biologics"
      }, 
      {
        "id": "http://scigraph.springernature.com/ontologies/subjects/diagnostics"
      }, 
      {
        "id": "http://scigraph.springernature.com/ontologies/subjects/drug-regulation"
      }, 
      {
        "id": "http://scigraph.springernature.com/ontologies/subjects/biomarkers"
      }, 
      {
        "id": "http://scigraph.springernature.com/ontologies/subjects/target-validation"
      }, 
      {
        "id": "http://scigraph.springernature.com/ontologies/subjects/pharmacology"
      }, 
      {
        "id": "http://scigraph.springernature.com/ontologies/subjects/target-identification"
      }, 
      {
        "id": "http://scigraph.springernature.com/ontologies/subjects/pharmaceutics"
      }, 
      {
        "id": "http://scigraph.springernature.com/ontologies/subjects/drug-safety"
      }, 
      {
        "id": "http://scigraph.springernature.com/ontologies/subjects/drug-delivery"
      }, 
      {
        "id": "http://scigraph.springernature.com/ontologies/subjects/toxicology"
      }, 
      {
        "id": "http://scigraph.springernature.com/ontologies/subjects/clinical-trials"
      }, 
      {
        "id": "http://scigraph.springernature.com/ontologies/subjects/medicinal-chemistry"
      }
    ], 
    "skos:prefLabel": [
      {
        "@language": "en", 
        "@value": "Drug discovery"
      }
    ], 
    "type": [
      "http://www.w3.org/2004/02/skos/core#Concept", 
      "http://ns.nature.com/terms/Subject"
    ]
  }, 
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "dcterms:description": [
      {
        "@language": "en", 
        "@value": "The Nature Subjects Taxonomy is a polyhierarchical categorization of scholarly subject areas which are used for the indexing of content by Springer Nature."
      }
    ], 
    "dcterms:title": [
      {
        "@language": "en", 
        "@value": "Nature Subjects Taxonomy"
      }
    ], 
    "id": "http://scigraph.springernature.com/ontologies/subjects/", 
    "sdDataset": "onto_subjects", 
    "skos:hasTopConcept": [
      {
        "id": "http://scigraph.springernature.com/ontologies/subjects/physical-sciences"
      }, 
      {
        "id": "http://scigraph.springernature.com/ontologies/subjects/DEPRECATED"
      }, 
      {
        "id": "http://scigraph.springernature.com/ontologies/subjects/business-and-commerce"
      }, 
      {
        "id": "http://scigraph.springernature.com/ontologies/subjects/humanities"
      }, 
      {
        "id": "http://scigraph.springernature.com/ontologies/subjects/social-science"
      }, 
      {
        "id": "http://scigraph.springernature.com/ontologies/subjects/health-sciences"
      }, 
      {
        "id": "http://scigraph.springernature.com/ontologies/subjects/scientific-community-and-society"
      }, 
      {
        "id": "http://scigraph.springernature.com/ontologies/subjects/earth-and-environmental-sciences"
      }, 
      {
        "id": "http://scigraph.springernature.com/ontologies/subjects/biological-sciences"
      }
    ], 
    "type": [
      "http://www.w3.org/2004/02/skos/core#ConceptScheme"
    ]
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/ontologies/subjects/business-strategy-in-drug-development'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/ontologies/subjects/business-strategy-in-drug-development'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/ontologies/subjects/business-strategy-in-drug-development'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/ontologies/subjects/business-strategy-in-drug-development'


 

This table displays all metadata directly associated to this object as RDF triples.

147 TRIPLES      8 PREDICATES      17 URIs      3 LITERALS

Subject Predicate Object
1 sg:ontologies/subjects/business-strategy-in-drug-development sgo:license sg:explorer/license/
2 sgo:sdDataset onto_subjects
3 rdf:type npg:Subject
4 skos:Concept
5 rdfs:label Business strategy in drug development
6 skos:broader sg:ontologies/subjects/drug-discovery
7 skos:inScheme sg:ontologies/subjects/
8 skos:narrower sg:ontologies/subjects/intellectual-property
9 sg:ontologies/subjects/licensing
10 sg:ontologies/subjects/market-analysis
11 sg:ontologies/subjects/mergers-and-acquisitions
12 sg:ontologies/subjects/pharmacoeconomics
13 sg:ontologies/subjects/portfolio-management
14 sg:ontologies/subjects/public-private-partnerships
15 sg:ontologies/subjects/reimbursement
16 skos:prefLabel Business strategy in drug development
17 sg:ontologies/subjects/ dcterms:description The Nature Subjects Taxonomy is a polyhierarchical categorization of scholarly subject areas which are used for the indexing of content by Springer Nature.
18 dcterms:title Nature Subjects Taxonomy
19 sgo:sdDataset onto_subjects
20 rdf:type skos:ConceptScheme
21 skos:hasTopConcept sg:ontologies/subjects/DEPRECATED
22 sg:ontologies/subjects/biological-sciences
23 sg:ontologies/subjects/business-and-commerce
24 sg:ontologies/subjects/earth-and-environmental-sciences
25 sg:ontologies/subjects/health-sciences
26 sg:ontologies/subjects/humanities
27 sg:ontologies/subjects/physical-sciences
28 sg:ontologies/subjects/scientific-community-and-society
29 sg:ontologies/subjects/social-science
30 sg:ontologies/subjects/drug-discovery sgo:sdDataset onto_subjects
31 rdf:type npg:Subject
32 skos:Concept
33 rdfs:label Drug discovery
34 skos:altLabel Drug Prospecting
35 skos:broader sg:ontologies/subjects/biological-sciences
36 skos:definition Drug discovery is the process through which potential new medicines are identified. It involves a wide range of scientific disciplines, including biology, chemistry and pharmacology.
37 skos:inScheme sg:ontologies/subjects/
38 skos:narrower sg:ontologies/subjects/biologics
39 sg:ontologies/subjects/biomarkers
40 sg:ontologies/subjects/business-strategy-in-drug-development
41 sg:ontologies/subjects/clinical-trials
42 sg:ontologies/subjects/diagnostics
43 sg:ontologies/subjects/drug-delivery
44 sg:ontologies/subjects/drug-regulation
45 sg:ontologies/subjects/drug-safety
46 sg:ontologies/subjects/drug-screening
47 sg:ontologies/subjects/medicinal-chemistry
48 sg:ontologies/subjects/pharmaceutics
49 sg:ontologies/subjects/pharmacology
50 sg:ontologies/subjects/target-identification
51 sg:ontologies/subjects/target-validation
52 sg:ontologies/subjects/toxicology
53 skos:prefLabel Drug discovery
54 sg:ontologies/subjects/intellectual-property sgo:sdDataset onto_subjects
55 rdf:type npg:Subject
56 skos:Concept
57 rdfs:label Intellectual property
58 skos:altLabel Intellectual Properties
59 skos:broader sg:ontologies/subjects/business-strategy-in-drug-development
60 skos:definition Intellectual property (IP), such as patents, provides legal rights to the exclusive use of the output of creative efforts. For example, a patent on a drug could provide its owner with the right to exclusively market that drug for a defined period of time in exchange for detailed public disclosure of the drug’s characteristics, such as chemical structure.
61 skos:inScheme sg:ontologies/subjects/
62 skos:prefLabel Intellectual property
63 sg:ontologies/subjects/licensing sgo:sdDataset onto_subjects
64 rdf:type npg:Subject
65 skos:Concept
66 rdfs:label Licensing
67 skos:altLabel Institutional Personnel Licensure
68 Institutional Personnel Licensures
69 License
70 Licenses
71 Licensure
72 Licensures
73 Permit
74 Permits
75 skos:broader sg:ontologies/subjects/business-strategy-in-drug-development
76 skos:definition Licensing is widely used in the commercialization of intellectual property such as patents on drugs or technologies. The owner of the intellectual property grants the licensee the rights to use the intellectual property, typically in return for a payment, such as a fee or royalty.
77 skos:inScheme sg:ontologies/subjects/
78 skos:prefLabel Licensing
79 sg:ontologies/subjects/market-analysis sgo:sdDataset onto_subjects
80 rdf:type npg:Subject
81 skos:Concept
82 rdfs:label Market analysis
83 skos:broader sg:ontologies/subjects/business-strategy-in-drug-development
84 skos:definition Market analysis seeks to understand the dynamics of markets, with the goal of informing business strategies. For example, analysis of the current and potential future markets for drugs to treat particular diseases is used by pharmaceutical companies in decisions about where to invest in drug research and development.
85 skos:inScheme sg:ontologies/subjects/
86 skos:prefLabel Market analysis
87 sg:ontologies/subjects/mergers-and-acquisitions sgo:sdDataset onto_subjects
88 rdf:type npg:Subject
89 skos:Concept
90 rdfs:label Mergers and acquisitions
91 skos:broader sg:ontologies/subjects/business-strategy-in-drug-development
92 skos:definition Mergers and acquisitions (M&A) involve the buying, selling, dividing and combining of different companies to achieve company goals. For example, in the pharmaceutical industry, large companies may acquire small companies with a view to enhancing the overall pipeline of potential medicines they are developing or to gain access to a proprietary technology.
93 skos:inScheme sg:ontologies/subjects/
94 skos:prefLabel Mergers and acquisitions
95 sg:ontologies/subjects/pharmacoeconomics sgo:sdDataset onto_subjects
96 rdf:type npg:Subject
97 skos:Concept
98 rdfs:label Pharmacoeconomics
99 skos:altLabel Pharmaceutical Economics
100 skos:broader sg:ontologies/subjects/business-strategy-in-drug-development
101 skos:definition Pharmacoeconomics is the scientific discipline concerned with the cost and value of drugs, often with the goal of optimizing the allocation of healthcare resources. For example, pharmacoeconomic studies may compare the costs of various drugs with the outcomes, such as benefits to patients receiving the drugs and costs saved by healthcare systems owing to effective treatment or prevention of a disease.
102 skos:inScheme sg:ontologies/subjects/
103 skos:prefLabel Pharmacoeconomics
104 sg:ontologies/subjects/portfolio-management sgo:sdDataset onto_subjects
105 rdf:type npg:Subject
106 skos:Concept
107 rdfs:label Portfolio management
108 skos:broader sg:ontologies/subjects/business-strategy-in-drug-development
109 skos:definition Larger drug companies attempt to ensure consistent financial performance by managing a portfolio of products at different stages of development, from preclinical studies through to marketed products. Generally, only marketed products are bringing in revenue, and they will eventually lose patent protection and revenue from them will drop substantially, and so there is a need to develop new marketed products to maintain overall revenue, but these have a risk of failure in development to account for.
110 skos:inScheme sg:ontologies/subjects/
111 skos:prefLabel Portfolio management
112 sg:ontologies/subjects/public-private-partnerships sgo:sdDataset onto_subjects
113 rdf:type npg:Subject
114 skos:Concept
115 rdfs:label Public–private partnerships
116 skos:altLabel Public Private Cooperation
117 Public Private Partnerships
118 Public Private Sector Cooperation
119 Public Private Sector Partnerships
120 Public-Private Cooperation
121 Public-Private Cooperations
122 Public-Private Partnership
123 Public-Private Partnerships
124 Public-Private Sector Cooperation
125 Public-Private Sector Cooperations
126 Public-Private Sector Partnership
127 Public-Private Sector Partnerships
128 skos:broader sg:ontologies/subjects/business-strategy-in-drug-development
129 skos:definition Public–private partnerships are collaborations between publicly funded organizations such as academic institutions and for-profit organizations such as pharmaceutical companies. They are often set up to benefit from complementary assets of each party, such as expertise in disease biology in academic institutions and expertise and financial resources for clinical development in companies.
130 skos:inScheme sg:ontologies/subjects/
131 skos:prefLabel Public–private partnerships
132 sg:ontologies/subjects/reimbursement sgo:sdDataset onto_subjects
133 rdf:type npg:Subject
134 skos:Concept
135 rdfs:label Reimbursement
136 skos:altLabel Incentive Reimbursement
137 Incentive Reimbursements
138 Pay for Performance
139 skos:broader sg:ontologies/subjects/business-strategy-in-drug-development
140 skos:definition Reimbursement is a key component of market access for a new therapeutic intervention; once it has been approved for marketing in a region or country, and its initial price determined, the manufacturer typically submits an application to an organization (such as an insurance company or a government bodies in countries that provide government-funded healthcare) that decides whether it will reimburse the company for its use by doctors to treat patients.
141 skos:inScheme sg:ontologies/subjects/
142 skos:prefLabel Reimbursement
143 skos:Concept sgo:sdDataset for_codes
144 rdf:type rdfs:Class
145 rdfs:Resource
146 rdfs:subClassOf rdfs:Resource
147 skos:Concept
 




Preview window. Press ESC to close (or click here)


...